GLP-1 Weight Loss
GLP-1 drugs mimic the natural GLP-1 hormone to regulate appetite, blood sugar, and digestion.
Initially developed for type 2 diabetes, they aid weight loss by reducing cravings, slowing stomach emptying, and helping individuals feel fuller longer.
These drugs improve physical health, boost self-esteem, enhance body image, reduce anxiety, and increase energy and mobility, leading to a more active lifestyle and better overall quality of life.
Tirzepatide
A dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, used for the treatment of type 2 diabetes. It is designed to improve glycemic control, body weight, and other metabolic parameters in people with type 2 diabetes. The combination of GIP and GLP-1 receptor agonism in tirzepatide is intended to provide complementary mechanisms of action to address multiple facets of type 2 diabetes pathophysiology, including insulin secretion, insulin sensitivity, and appetite regulation.
Tirzepatide has been studied in clinical trials, and results have shown promising efficacy in reducing HbA1c (a measure of long-term blood sugar control) and body weight compared to other antidiabetic medications.
Suggested Dosing Information
Week 1-4: 2.5mg weekly
Week 5-8: 5mg weekly
Week 9-12: 7.5mg weekly
Week 13-16: 10mg weekly
Week 17-20: 12.5mg weekly
Week 21+ 15mg weekly
Enhanced Glycemic Control: Tirzepatide has shown superior efficacy in lowering blood sugar levels compared to other GLP-1 receptor agonists. It improves insulin secretion in a glucose-dependent manner, reduces glucagon secretion, and delays gastric emptying, all of which contribute to improved glycemic control.
Significant Weight Loss: Clinical trials have demonstrated that tirzepatide can lead to substantial weight loss, often surpassing results seen with other medications. This effect is due to its dual action on GIP and GLP-1 receptors, which not only helps to control blood sugar but also suppresses appetite and increases energy expenditure.
Convenience of Use: Tirzepatide is administered via subcutaneous injection once a week, which can be more convenient for patients compared to medications requiring daily dosing, thereby improving adherence to the treatment regimen.
Treating Obesity in Non-Diabetics: Given its significant impact on weight reduction, tirzepatide is being used as a weight loss treatment in individuals without diabetes. No minimum BMI or qualifying medical conditions required. Individualized dosing to meet all ranges of weight loss goals.